中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Research advances in noninvasive diagnosis of liver fibrosis in autoimmune liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.11.026
Research funding:

General Program of Jiangxi Natural Science Foundation (20192BAB205090);

Science and Technology Project of Jiangxi Province Administration of Traditional Chinese Medicine (2020A0174)

More Information
  • Corresponding author: YANG Lixia, ylx35366@163.com (ORCID: 0000-0002-8167-1521)
  • Received Date: 2023-03-14
  • Accepted Date: 2023-05-10
  • Published Date: 2023-11-28
  • Autoimmune liver diseases (ALD) are a group of chronic inflammatory liver diseases mediated by autoimmune response and can progress to liver fibrosis, liver cirrhosis, and even liver failure. Early diagnosis, early treatment, and dynamic follow-up of liver fibrosis in ALD may help to improve the prognosis of the disease and even reverse early-stage liver cirrhosis. Due to the limitations and potential risks of liver biopsy, the search for noninvasive techniques has become a research hotspot in the field of liver fibrosis. This article reviews the recent research advances in serum markers and imaging techniques for liver fibrosis in ALD and analyzes the advantages and disadvantages of each detection method and their development trends.

     

  • [1]
    FANG JM, CHENG J, CHANG MF, et al. Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint[J]. Mod Pathol, 2021, 34( 10): 1955- 1962. DOI: 10.1038/s41379-021-00851-5.
    [2]
    NEUBERGER J, PATEL J, CALDWELL H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology[J]. Gut, 2020, 69( 8): 1382- 1403. DOI: 10.1136/gutjnl-2020-321299.
    [3]
    GATSELIS NK, TORNAI T, SHUMS Z, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients[J]. World J Gastroenterol, 2020, 26( 34): 5130- 5145. DOI: 10.3748/wjg.v26.i34.5130.
    [4]
    YAO M, WANG L, LEUNG P, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54( 2): 282- 294. DOI: 10.1007/s12016-017-8655-y.
    [5]
    YAO M, WANG L, WANG J, et al. Diagnostic value of serum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis[J]. Dis Markers, 2022, 2022: 4253566. DOI: 10.1155/2022/4253566.
    [6]
    WANG X, HE Y, MACKOWIAK B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases[J]. Gut, 2021, 70( 4): 784- 795. DOI: 10.1136/gutjnl-2020-322526.
    [7]
    TADOKORO T, MORISHITA A, MASAKI T. Diagnosis and therapeutic management of liver fibrosis by microRNA[J]. Int J Mol Sci, 2021, 22( 15). DOI: 10.3390/ijms22158139.
    [8]
    MIGITA K, KOMORI A, KOZURU H, et al. Circulating microRNA profiles in patients with Type-1 autoimmune hepatitis[J]. PLoS One, 2015, 10( 11): e0136908. DOI: 10.1371/journal.pone.0136908.
    [9]
    TU H, CHEN D, CAI C, et al. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation[J]. J Cell Mol Med, 2020, 24( 2): 1256- 1267. DOI: 10.1111/jcmm.14750.
    [10]
    FERNÁNDEZ-RAMOS D, FERNÁNDEZ-TUSSY P, LOPITZ-OTSOA F, et al. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis[J]. Cell Death Dis, 2018, 9( 10): 958. DOI: 10.1038/s41419-018-1014-y.
    [11]
    PAN Y, WANG J, HE L, et al. MicroRNA-34a promotes EMT and liver fibrosis in primary biliary cholangitis by regulating TGF-β1/smad pathway[J]. J Immunol Res, 2021, 2021: 6890423. DOI: 10.1155/2021/6890423.
    [12]
    WAN Y, ZHOU T, SLEVIN E, et al. Liver-specific deletion of microRNA-34a alleviates ductular reaction and liver fibrosis during experimental cholestasis[J]. FASEB J, 2023, 37( 2): e22731. DOI: 10.1096/fj.202201453R.
    [13]
    BEKKI Y, YOSHIZUMI T, SHIMODA S, et al. Hepatic stellate cells secreting WFA+-M2BP: Its role in biological interactions with Kupffer cells[J]. J Gastroenterol Hepatol, 2017, 32( 7): 1387- 1393. DOI: 10.1111/jgh.13708.
    [14]
    FENG S, WANG Z, ZHAO Y, et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis[J]. Sci Rep, 2020, 10( 1): 10582. DOI: 10.1038/s41598-020-67471-y.
    [15]
    NISHIKAWA H, ENOMOTO H, IWATA Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis[J]. Hepatol Res, 2016, 46( 7): 613- 621. DOI: 10.1111/hepr.12596.
    [16]
    UMEMURA T, JOSHITA S, SEKIGUCHI T, et al. Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol, 2015, 110( 6): 857- 864. DOI: 10.1038/ajg.2015.118.
    [17]
    UMETSU S, INUI A, SOGO T, et al. Usefulness of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in children with primary sclerosing cholangitis[J]. Hepatol Res, 2018, 48( 5): 355- 363. DOI: 10.1111/hepr.13004.
    [18]
    KARTASHEVA-EBERTZ D, GASTON J, LAIR-MEHIRI L, et al. IL-17A in human liver: Significant source of inflammation and trigger of liver fibrosis initiation[J]. Int J Mol Sci, 2022, 23( 17). DOI: 10.3390/ijms23179773.
    [19]
    LUO SY, LI TT, WANG YQ, et al. Diagnostic performance of peripheral blood Treg/Th17 cells and their related cytokines in predicting significant liver fibrosis in patients with primary biliary cholangitis[J]. J Prac Hepatol, 2022, 25( 5): 673- 676. DOI: 10.3969/j.issn.1672-5069.2022.05.017.

    骆苏彦, 李婷婷, 王亚奇, 等. 原发性胆汁性胆管炎患者外周血Treg/Th17细胞相关细胞因子水平变化[J]. 实用肝脏病杂志, 2022, 25( 5): 673- 676. DOI: 10.3969/j.issn.1672-5069.2022.05.017.
    [20]
    JIA H, CHEN J, ZHANG X, et al. IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer-T cells promote liver fibrosis in patients with primary biliary cholangitis[J]. J Leukoc Biol, 2022, 112( 5): 1079- 1087. DOI: 10.1002/JLB.2A0622-586RRRR.
    [21]
    BAUER A, HABIOR A. Concentration of serum matrix metalloproteinase-3 in patients with primary biliary cholangitis[J]. Front Immunol, 2022, 13: 885229. DOI: 10.3389/fimmu.2022.885229.
    [22]
    HUANG B, LYU Z, QIAN Q, et al. NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis[J]. J Hepatol, 2022, 77( 5): 1311- 1324. DOI: 10.1016/j.jhep.2022.06.014.
    [23]
    POVERO D, TAMEDA M, EGUCHI A, et al. Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis[J]. Sci Rep, 2022, 12( 1): 3027. DOI: 10.1038/s41598-022-06809-0.
    [24]
    LIU R, LI X, ZHU W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis[J]. Hepatology, 2019, 70( 4): 1317- 1335. DOI: 10.1002/hep.30662.
    [25]
    ZHANG J, LYU Z, LI B, et al. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases[J]. Hepatology, 2023, 78( 1): 10- 25. DOI: 10.1097/HEP.0000000000000317.
    [26]
    DONG B, CHEN Y, LYU G, et al. Aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in patients with autoimmune hepatitis: A meta-analysis[J]. Front Immunol, 2022, 13: 892454. DOI: 10.3389/fimmu.2022.892454.
    [27]
    JIANG M, YAN X, SONG X, et al. Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis[J]. Medicine(Baltimore), 2020, 99( 22): e20502. DOI: 10.1097/MD.0000000000020502.
    [28]
    AVCIOĞLU U, ERUZUN H, USTAOĞLU M. The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis[J]. Medicine(Baltimore), 2022, 101( 40): e30626. DOI: 10.1097/MD.0000000000030626.
    [29]
    SAYAR S, GOKCEN P, AYKUT H, et al. Can simple non-invasive fibrosis models determine prognostic indicators(fibrosis and treatment response) of primary biliary cholangitis?[J]. Sisli Etfal Hastan Tip Bul, 2021, 55( 3): 412- 418. DOI: 10.14744/SEMB.2021.95825.
    [30]
    HU M, YOU Z, LI Y, et al. Serum biomarkers for autoimmune hepatitis type 1: the case for CD48 and a review of the literature[J]. Clin Rev Allergy Immunol, 2022, 63( 3): 342- 356. DOI: 10.1007/s12016-022-08935-z.
    [31]
    YANG ZR, WANG LH, LI Y, et al. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. J Clin Hepatol, 2022, 38( 1): 97- 103. DOI: 10.3969/j.issn.1001-5256.2022.01.015.

    杨志然, 王林恒, 李园, 等. 瞬时弹性成像技术对自身免疫性肝病肝纤维化分期诊断价值的Meta分析[J]. 临床肝胆病杂志, 2022, 38( 1): 97- 103. DOI: 10.3969/j.issn.1001-5256.2022.01.015.
    [32]
    XU Q, SHENG L, BAO H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2017, 32( 3): 639- 644. DOI: 10.1111/jgh.13508.
    [33]
    HARTL J, DENZER U, EHLKEN H, et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis[J]. J Hepatol, 2016, 65( 4): 769- 775. DOI: 10.1016/j.jhep.2016.05.023.
    [34]
    HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68( 4): 754- 763. DOI: 10.1016/j.jhep.2017.11.020.
    [35]
    CORPECHOT C, CARRAT F, POUJOL-ROBERT A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis[J]. Hepatology, 2012, 56( 1): 198- 208. DOI: 10.1002/hep.25599.
    [36]
    CRISTOFERI L, CALVARUSO V, OVERI D, et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in naïve patients with primary biliary cholangitis: A dual cut-off approach[J]. Hepatology, 2021, 74( 3): 1496- 1508. DOI: 10.1002/hep.31810.
    [37]
    CORPECHOT C, CARRAT F, GAOUAR F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis[J]. J Hepatol, 2022, 77( 6): 1545- 1553. DOI: 10.1016/j.jhep.2022.06.017.
    [38]
    CORPECHOT C, GAOUAR F, NAGGAR A EL, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis[J]. Gastroenterology, 2014, 146( 4): 970- 979; quiz e15- 16. DOI: 10.1053/j.gastro.2013.12.030.
    [39]
    WU HM, SHENG L, WANG Q, et al. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome[J]. World J Gastroenterol, 2018, 24( 6): 737- 743. DOI: 10.3748/wjg.v24.i6.737.
    [40]
    ZENG J, HUANG ZP, ZHENG J, et al. Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases[J]. World J Gastroenterol, 2017, 23( 26): 4839- 4846. DOI: 10.3748/wjg.v23.i26.4839.
    [41]
    XING X, YAN Y, SHEN Y, et al. Liver fibrosis with two-dimensional shear-wave elastography in patients with autoimmune hepatitis[J]. Expert Rev Gastroenterol Hepatol, 2020, 14( 7): 631- 638. DOI: 10.1080/17474124.2020.1779589.
    [42]
    YAN Y, XING X, LU Q, et al. Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis[J]. Dig Liver Dis, 2020, 52( 5): 555- 560. DOI: 10.1016/j.dld.2020.02.002.
    [43]
    YAN YL, XING X, WANG Y, et al. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome[J]. World J Gastroenterol, 2022, 28( 18): 2021- 2033. DOI: 10.3748/wjg.v28.i18.2021.
    [44]
    SOH EG, LEE YH, KIM YR, et al. Usefulness of 2D shear wave elastography for the evaluation of hepatic fibrosis and treatment response in patients with autoimmune hepatitis[J]. Ultrasonography, 2022, 41( 4): 740- 749. DOI: 10.14366/usg.21266.
    [45]
    GALINA P, ALEXOPOULOU E, MENTESSIDOU A, et al. Diagnostic accuracy of two-dimensional shear wave elastography in detecting hepatic fibrosis in children with autoimmune hepatitis, biliary atresia and other chronic liver diseases[J]. Pediatr Radiol, 2021, 51( 8): 1358- 1368. DOI: 10.1007/s00247-020-04959-9.
    [46]
    WANG J, MALIK N, YIN M, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis[J]. World J Gastroenterol, 2017, 23( 5): 859- 868. DOI: 10.3748/wjg.v23.i5.859.
    [47]
    OSMAN KT, MASELLI DB, IDILMAN IS, et al. Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis[J]. J Clin Gastroenterol, 2021, 55( 5): 449- 457. DOI: 10.1097/MCG.0000000000001433.
    [48]
    EATON JE, DZYUBAK B, VENKATESH SK, et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis[J]. J Gastroenterol Hepatol, 2016, 31( 6): 1184- 1190. DOI: 10.1111/jgh.13263.
    [49]
    TAFUR M, CHEUNG A, MENEZES RJ, et al. Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography[J]. Eur Radiol, 2020, 30( 7): 3735- 3747. DOI: 10.1007/s00330-020-06728-6.
    [50]
    ISMAIL MF, HIRSCHFIELD GM, HANSEN B, et al. Evaluation of quantitative MRCP(MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores[J]. Eur Radiol, 2022, 32( 1): 67- 77. DOI: 10.1007/s00330-021-08142-y.
    [51]
    JHAVERI KS, HOSSEINI-NIK H, SADOUGHI N, et al. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis[J]. Eur Radiol, 2019, 29( 2): 1039- 1047. DOI: 10.1007/s00330-018-5619-4.
    [52]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 50- 61. DOI: 10.3969/j.issn.1001-5256.2022.01.009.

    中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 50- 61. DOI: 10.3969/j.issn.1001-5256.2022.01.009.
  • Relative Articles

    [1]Jialuo WANG, Yufeng ZHENG, Qingfang XIONG, Yongfeng YANG. Etiology spectrum, clinical features, and gene mutations of unexplained intrahepatic cholestasis: An analysis of 62 cases[J]. Journal of Clinical Hepatology, 2025, 41(2): 307-313. doi: 10.12449/JCH250217
    [2]Xiaoyao LI, Jianfeng DUAN, Dacheng WANG, Xiancheng CHEN, Beiyuan ZHANG, Wenkui YU. Recurrent hypertriglyceridemic acute pancreatitis in an adult patient caused by the de novo mutation of p.K327N in the GPD1 gene: A case report[J]. Journal of Clinical Hepatology, 2024, 40(2): 361-364. doi: 10.12449/JCH240222
    [3]Sa LYU, Bing ZHU, Tianjiao XU, Shaoli YOU. The extreme reduction in cholinesterase caused by compound heterozygous mutations in the BCHE gene: A case report[J]. Journal of Clinical Hepatology, 2024, 40(10): 2075-2078. doi: 10.12449/JCH241023
    [4]Shuduo WU, Yibo ZHAN, Xinhua LI, Changlei XU, Minling CAO, Xiaoling CHI. Hereditary hemochromatosis with multiple organ damage caused by HJV gene mutation in adults: A case report[J]. Journal of Clinical Hepatology, 2022, 38(11): 2571-2574. doi: 10.3969/j.issn.1001-5256.2022.11.026
    [5]Dan YANG, Cuiwei ZHANG, Mingming DENG. A compound heterozygous mutation in the ATP7B gene with acute fatty liver of pregnancy: A case report[J]. Journal of Clinical Hepatology, 2022, 38(1): 167-169. doi: 10.3969/j.issn.1001-5256.2022.01.027
    [6]Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
    [7]Lei HUA, Quan SUN, Wenbin XU, Long ZHANG, Gongqiang WANG. ABCB4 gene mutation-associated liver cirrhosis misdiagnosed as Wilson's disease: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1419-1420. doi: 10.3969/j.issn.1001-5256.2021.06.039
    [8]Chengyu ZHU, Qi CHEN, Zhongxin FENG. Hereditary hemochromatosis caused by mutation in the SLC40A1 gene: A case report[J]. Journal of Clinical Hepatology, 2021, 37(5): 1180-1182. doi: 10.3969/j.issn.1001-5256.2021.05.041
    [9]Yuhang WENG, Yongfeng YANG. Association between genotype and phenotype of ABCB4 gene mutation[J]. Journal of Clinical Hepatology, 2021, 37(11): 2723-2726. doi: 10.3969/j.issn.1001-5256.2021.11.052
    [10]Yong ZHANG, Zhengfa MAO. Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 84-88. doi: 10.3969/j.issn.1001-5256.2021.01.017
    [11]Yang Fan, Wang YiRou, Yu XiaoDan, Ma Xiong, Wang XiuMin. Congenital hepatic fibrosis with retinitis pigmentosa caused by mutations of the TMEM67 gene and CNGB1 gene: A case report[J]. Journal of Clinical Hepatology, 2020, 36(7): 1593-1595. doi: 10.3969/j.issn.1001-5256.2020.07.029
    [12]Liang Chen, Bai Li, Zheng SuJun. Research advances in mutation characteristics of the UGT1A1 gene in Gilbert syndrome and its influence on intrahepatic and extrahepatic systems[J]. Journal of Clinical Hepatology, 2019, 35(7): 1632-1635. doi: 10.3969/j.issn.1001-5256.2019.07.046
    [13]Li Ning, Zhang Xin, Li Rui, Jiao Lin. Hepatolenticular degeneration with MTHFR gene mutation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(11): 2549-2550. doi: 10.3969/j.issn.1001-5256.2019.11.033
    [14]Zhou HuaBang, Hu HePing. Challenges in precise treatment for primary liver cancer based on gene mutation[J]. Journal of Clinical Hepatology, 2017, 33(7): 1209-1210. doi: 10.3969/j.issn.1001-5256.2017.07.001
    [15]Pang Ting, Xing HuiChun. Correlation between drug-resistance gene mutations and hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(1): 82-86. doi: 10.3969/j.issn.1001-5256.2017.01.017
    [16]Lu: TingXia, Zhang Wei, Li XiaoJin, Xu AnJian, Zhao XinYan, Ou XiaoJuan, Huang Jian. Characteristics of gene mutation in Chinese patients with hereditary hemochromatosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1571-1574. doi: 10.3969/j.issn.1001-5256.2016.08.028
    [17]Hu AiRong, Hu Ting. Common mutations of hepatitis B virus and their clinical significance[J]. Journal of Clinical Hepatology, 2016, 32(8): 1463-1467. doi: 10.3969/j.issn.1001-5256.2016.08.006
    [18]Mao WeiWu, Du Peng, Zhang WenJie, Li Jing, Qu Yan, Shi HuaiYuan, Wang YanXia. Impact of HCV 5′NCR genetic mutation on standard program of anti-HCV therapy[J]. Journal of Clinical Hepatology, 2015, 31(4): 585-587. doi: 10.3969/j.issn.1001-5256.2015.04.026
    [19]Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
  • Cited by

    Periodical cited type(11)

    1. 鞠迪,李汨,韩曼,房冰莹,闫曙光,李京涛. 益脾养肝方对大鼠肝癌前病变肝干细胞恶性转化的影响和作用机制. 临床肝胆病杂志. 2022(04): 865-871 . 本站查看
    2. 陈艳,王桂洁,余青. 当归注射液对肝硬化大鼠门静脉压力及TGFβ1/PI3K通路的调节作用. 中西医结合肝病杂志. 2022(07): 617-621 .
    3. 刘蕊洁,曹旭,杨先照,梁亦骏,叶永安. 益肝消癥方联合恩替卡韦对乙型肝炎病毒诱导肝星状细胞增殖、凋亡的调节作用. 中华中医药杂志. 2022(11): 6796-6800 .
    4. 刘蕊洁,杨先照,张嘉鑫,叶永安. 益肝消癥方对大鼠肝癌前病变肝细胞凋亡因子Bcl-2、Bax mRNA及蛋白质表达的影响. 中西医结合肝病杂志. 2021(01): 56-59 .
    5. 杨洁,贺武斌,安妮,孔雯聪,苏荣健,王学哲. 葡萄糖调节蛋白78对肝癌细胞放射敏感性的调控作用及其机制. 吉林大学学报(医学版). 2021(04): 888-895 .
    6. 宁麟,孙建光. 原发性肝癌癌前病变中西医研究进展. 世界科学技术-中医药现代化. 2021(10): 3590-3598 .
    7. 黄倩,李京涛,张海博,魏海梁,闫曙光,常占杰. 李京涛诊治肝癌癌前病变经验探析. 中西医结合肝病杂志. 2020(03): 246-248 .
    8. 邓琰,吴凡,陈芦斌,李宁宇,寇伟伟. 内镜下食管静脉曲张套扎术治疗乙肝肝硬化后25-(OH)D_3水平与出血风险的关系. 现代消化及介入诊疗. 2020(06): 761-764 .
    9. 吴杰,李京涛,魏海梁,闫曙光,范妤,郭英君,常占杰. microRNA调控肝星状细胞活化干预肝癌癌前病变的研究进展. 临床肝胆病杂志. 2020(07): 1650-1654 . 本站查看
    10. 张丽泳,欧阳晓晖,苏秀兰. 线粒体自噬的分子机制及其对肝脏疾病潜在治疗价值的研究进展. 现代免疫学. 2019(01): 68-71 .
    11. 张红宇,李娟,余祖江,江河清,梁红霞,武淑环. 调控miR-495、P4HA2的表达对肝纤维化和肝细胞癌发生机制研究. 中西医结合肝病杂志. 2019(04): 313-316 .

    Other cited types(7)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (459) PDF downloads(56) Cited by(18)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return